Share This Page
Drug Price Trends for PROPAFENONE HCL ER
✉ Email this page to a colleague
Average Pharmacy Cost for PROPAFENONE HCL ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PROPAFENONE HCL ER 225 MG CAP | 64380-0184-02 | 0.37785 | EACH | 2025-12-17 |
| PROPAFENONE HCL ER 225 MG CAP | 16714-0825-01 | 0.37785 | EACH | 2025-12-17 |
| PROPAFENONE HCL ER 225 MG CAP | 64380-0184-01 | 0.37785 | EACH | 2025-12-17 |
| PROPAFENONE HCL ER 225 MG CAP | 00591-2285-60 | 0.37785 | EACH | 2025-12-17 |
| PROPAFENONE HCL ER 225 MG CAP | 59651-0276-60 | 0.37785 | EACH | 2025-12-17 |
| PROPAFENONE HCL ER 225 MG CAP | 00832-0740-60 | 0.37785 | EACH | 2025-12-17 |
| PROPAFENONE HCL ER 225 MG CAP | 16571-0736-06 | 0.37785 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Propafenone HCl ER
Introduction
Propafenone HCl Extended Release (ER) is a class IC antiarrhythmic agent indicated primarily for the treatment of atrial fibrillation, atrial flutter, and ventricular arrhythmias. As a generic medication with established long-term use, its market dynamics are shaped by evolving clinical guidelines, competition, patent status, and manufacturing trends. This analysis explores current market landscape, key drivers, challenges, and forecasts to provide actionable insights for stakeholders.
Market Landscape Overview
1. Therapeutic Indications and Clinical Positioning
Propafenone HCl ER is valued for its efficacy in maintaining sinus rhythm and controlling ventricular arrhythmias. It is often favored in patients who require oral, once-daily dosing, beneficial for adherence. Its role in arrhythmia management hierarchically positions it within a competitive antiarrhythmic segment dominated by drugs like flecainide, amiodarone, and sotalol.
2. Regulatory Status and Patent Landscape
Propafenone was FDA-approved in 1980. The extended-release formulation leverages improved pharmacokinetics, but no recent patent protections currently exist, ushering in generic competition. According to the FDA Orange Book[^1], patent protections have expired, allowing multiple generics to enter the market since the early 2010s, which has precipitated a decline in branded product revenues.
3. Market Size and Penetration
The global antiarrhythmic drugs market was valued at approximately USD 4 billion in 2022, with a projected CAGR of 4-6% over the next five years[^2]. Propafenone’s market share within this segment remains modest but stable, primarily driven by prescription patterns in North America and Europe. The prevalence of atrial fibrillation (AF), estimated at 33.5 million globally, directly correlates with potential demand for antiarrhythmic therapies, including propafenone[^3].
Current Market Drivers
4. Clinical Guidelines and Practice Trends
Guideline updates, such as those from the American College of Cardiology (ACC), emphasize patient-specific selection of antiarrhythmics. Propafenone’s favorable oral bioavailability and once-daily dosing support its continued utilization, especially in outpatient settings.
5. Generic Competition and Pricing
The proliferation of generics has driven prices downward. In the United States, average retail prices for propafenone HCl ER range from USD 0.30 to USD 1.00 per tablet, depending on dosage and pharmacy discounts[^4]. This competitive pricing accelerates accessibility but constrains profit margins for manufacturers.
6. Market Penetration in Emerging Economies
Emerging markets, with expanding healthcare infrastructure and rising AF prevalence, present growth opportunities. Local generic manufacturers and regional distribution channels facilitate increased adoption, but price sensitivity remains a critical factor.
Market Challenges
7. Patent Expiry and Generic Saturation
Patent expirations have led to intensifying price competition. While this benefits healthcare systems and patients, it compresses margins for manufacturers and diminishes branded product revenue streams.
8. Safety Profile and Side Effect Concerns
Propafenone’s proarrhythmic potential and contraindications in asthma or conduction disturbances warrant cautious prescribing. Safety concerns may limit market expansion, particularly amid the advent of newer drugs with favorable safety profiles.
9. Availability of Alternative Therapies
The emergence of catheter ablation techniques and newer antiarrhythmics (e.g., dronedarone, dofetilide) offers alternative management strategies, potentially reducing reliance on pharmacotherapy for arrhythmia control.
Price Projection Outlook (2023-2028)
10. Short-term Future (1–2 years)
Given the maturity of the market and the dominance of generics, direct price reductions are anticipated. Wholesale acquisition costs (WAC) are expected to decline by 10-15% annually, reflecting increased competition. Market volumes are projected to stabilize with minimal growth, constrained by emerging alternatives and treatment guidelines.
11. Medium to Long-term Outlook (3–5 years)
Price stabilization or slight decreases are forecasted, with average retail prices plateauing due to market saturation. Nevertheless, in emerging markets, localized price increases could occur owing to supply chain dynamics and import tariffs. Overall, expected weighted average prices may decrease by an aggregate of 15-20% over five years.
12. Influencing Factors
- Patent and regulatory landscape: No new patents or exclusivities are expected, maintaining high generic penetration.
- Market penetration: Slow growth in high-income regions; potential increases in developing countries.
- Healthcare policy: Cost containment initiatives could further pressure prices.
- Innovation: Lack of new formulations or delivery systems limits price growth potential.
Competitive Dynamics
13. Key Market Players
Major pharmaceutical companies, including multiple generics firms and regional players, participate in propafenone ER manufacturing. Generic manufacturers such as Teva, Mylan, and Sandoz dominate due to patent expiry, with branded versions largely phased out or available through limited channels.
14. Pricing Strategies
Price competition often results in aggressive discounts, pharmacy benefit manager negotiations, and bundled reimbursement strategies, further contributing to downward pressure on prices. Market consolidation may also influence pricing, with larger distributors exerting significant negotiation leverage.
Forecast Summary
| Year | Expected Average Retail Price (USD) | Market Volume Change | Revenue Projection |
|---|---|---|---|
| 2023 | $0.30 – $1.00 per tablet | Stable | Slight decline (~5–8%) |
| 2024 | $0.28 – $0.95 per tablet | Slight increase in emerging markets | Stabilized or marginal decline |
| 2025 | $0.27 – $0.90 per tablet | Slight growth in emerging economies | Stable with slight downward trend |
| 2026 | $0.26 – $0.88 per tablet | Moderate growth in emerging markets | Continuing downward pressure |
| 2027 | $0.25 – $0.85 per tablet | Steady growth in developing regions | Price stabilization |
Key Takeaways
-
Market maturity: Propafenone HCl ER’s patent expiry has led to widespread generic availability, resulting in prolonged price declines and market saturation.
-
Demand stability: Therapeutic relevance ensures steady but limited demand, primarily driven by AF prevalence, with growth prospects hindered by alternative therapies and procedural interventions.
-
Pricing outlook: Prices are expected to decrease by approximately 15-20% over the next five years, influenced heavily by generic competition and healthcare reimbursement policies.
-
Emerging markets: Opportunities exist for market expansion, driven by increasing AF diagnostics, healthcare infrastructure enhancement, and economic growth, albeit with higher price sensitivity.
-
Strategic considerations: Manufacturers should focus on optimizing supply chains, exploring niche indications, or developing value-added formulations to sustain margins amid aggressive pricing pressure.
Frequently Asked Questions (FAQs)
Q1: How does patent expiry impact the market price of propafenone HCl ER?
Patent expiry facilitates entry of multiple generic manufacturers, heightening competition and leading to significant price reductions. Market prices typically decline by 10-15% annually post-patent expiration.
Q2: Are there any upcoming innovations that could affect the propafenone HCl ER market?
Currently, no significant innovations or new formulations are imminent. Advances remain focused on procedural interventions and newer antiarrhythmic agents, which may influence long-term demand.
Q3: Which regions hold the highest growth potential for propafenone HCl ER?
Emerging economies in Asia, Latin America, and parts of Africa offer growth opportunities owing to increasing AF awareness, improving healthcare access, and expanding cardiovascular care infrastructure.
Q4: What are the primary drivers of price declines in this market?
Main drivers include patent expirations, intense generic competition, cost containment measures by healthcare authorities, and pricing pressures from large pharmacy chains and distributors.
Q5: How should pharmaceutical companies strategize to maintain profitability?
Strategies include developing niche or combination therapies, enhancing formulations for better compliance, expanding into less saturated markets, and engaging in strategic partnerships to optimize manufacturing and distribution.
Sources
[^1]: FDA Orange Book. List of patents and exclusivity information for propafenone.
[^2]: MarketsandMarkets, "Antiarrhythmic Drugs Market," 2022.
[^3]: Global Burden of Disease Study, 2021.
[^4]: GoodRx. Propafenone HCl ER prices.
Disclaimer: This analysis is based on publicly available data and market trends up to early 2023. Actual market conditions may vary due to unforeseen regulatory, economic, or clinical factors.
More… ↓
